OmniAb, Inc.
OmniAb, Inc. (OABI) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · OABI · as of Jun 8, 2026
Key Statistics
Explore OmniAb, Inc. Data
oabi stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 100.0%
The OABI analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $4.00, representing +75.44% upside from the current price of $2.28.
Competitors & Peers
oabi competitorsOABI
ARMP
CCCC
CDXS
IMDX
IPHAStock Performance
Full HistoryAbout OmniAb, Inc.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad s…
what is omniab, inc. · oabi stock overview · omniab, inc. company profile · who is omniab, inc. ceo · oabi NASDAQ · omniab, inc. headquarters · omniab, inc. business segments
About Stock Overview & Key Data
OmniAb, Inc. (OABI) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 30, 2021. As of the latest trading session, OABI stock price is $2.28, with a market capitalization of $271.5M. The stock has returned +52.00% over the past 12 months and +23.24% year-to-date.
According to 9 Wall Street analysts, the consensus rating for OmniAb, Inc. stock is Buy, with an average 12-month price target of $4.00. In fiscal year 2025, OmniAb, Inc. reported revenue of $18.7M and net income of -$64.8M. For detailed data — including OmniAb, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, OmniAb, Inc. (OABI) stock price is $2.28. The stock is traded on NASDAQ under the ticker symbol OABI. The 52-week range is $1.30 – $2.79.